title: (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma.
abstract: BACKGROUND
  We set out to evaluate the prognostic value of (18)F-fluorodeoxyglucose positron-emission tomography (pet) in patients with advanced (non-transplant-eligible) hepatocellular carcinoma (hcc) and to evaluate the correlation between standardized uptake values (suvs) and survival outcomes.
  
  
  METHODS
  We identified patients with hcc who, from 2005 to 2013, underwent pet imaging before any treatment. This retrospective study from our hcc database obtained complete follow-up data for the 63 identified patients.
  
  
  RESULTS
  Of the 63 patients, 10 underwent surgical resection, and 59 underwent locoregional therapy. In this cohort, 28 patients were pet-positive (defined as any lesion with a suv ≥ 4.0) before any therapy was given, and 35 patients were pet negative (all lesions with a suv < 4.0). On survival analysis, median survival was greater for the pet-negative than for the pet-positive patients: 29 months (range: 16.3-41.1 months) versus 12 months (range: 4.0-22.1 months) respectively, p = 0.0241. The pet-positive patients more often had large tumours (≥5 cm), poor differentiation, and extrahepatic disease, reflecting more aggressive tumours. On multivariate analysis, only pet positivity was associated with poor survival (p = 0.049).
  
  
  CONCLUSIONS
  Compared with pet-positive patients, pet-negative patients with hcc experienced longer survival. Imaging by pet can be of value in early prognostication for patients with hcc, especially patients receiving locoregional therapy for whom pathologic tumour differentiation is rarely available. This potential role for pet requires further validation in a prospective study.
authors.affiliation: Department of Surgery, McGill University Health Centre, Hepatopancreaticobiliary Research Unit, Montreal, QC.
authors.forename: E
authors.initials: E
authors.lastname: Simoneau
authors.affiliation: Department of Oncology, McGill University Health Centre, Montreal, QC. ; Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
authors.forename: M
authors.initials: M
authors.lastname: Hassanain
authors.affiliation: Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
authors.forename: A
authors.initials: A
authors.lastname: Madkhali
authors.affiliation: Department of Surgery, McGill University Health Centre, Hepatopancreaticobiliary Research Unit, Montreal, QC.
authors.forename: A
authors.initials: A
authors.lastname: Salman
authors.affiliation: Department of Gastroenterology, Division of Hepatology, McGill University Health Centre, Montreal, QC.
authors.forename: C G
authors.initials: CG
authors.lastname: Nudo
authors.affiliation: Department of Surgery, McGill University Health Centre, Hepatopancreaticobiliary Research Unit, Montreal, QC. ; Department of Oncology, McGill University Health Centre, Montreal, QC.
authors.forename: P
authors.initials: P
authors.lastname: Chaudhury
authors.affiliation: Department of Surgery, McGill University Health Centre, Hepatopancreaticobiliary Research Unit, Montreal, QC. ; Departments of Pathology and Anatomy and Cell Biology, McGill University Health Centre, Montreal, QC.
authors.forename: P
authors.initials: P
authors.lastname: Metrakos
keywords: Positron-emission tomography; hepatocellular carcinoma; outcomes; prognosis
references.citation: Oncologist. 2008 Jun;13(6):734-5; author reply 736-7
references.pmid: 18586929
references.citation: Lancet Oncol. 2001 Mar;2(3):157-64
references.pmid: 11902566
references.citation: J Clin Oncol. 2001 Jun 15;19(12):3037-44
references.pmid: 11408499
references.citation: J Gastroenterol. 2004 Oct;39(10):961-8
references.pmid: 15549449
references.citation: Cancer. 2011 Oct 15;117(20):4779-87
references.pmid: 21469082
references.citation: J Gastrointest Surg. 2011 Nov;15(11):2044-52
references.pmid: 21904962
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Nucl Med. 1995 Oct;36(10):1811-7
references.pmid: 7562048
references.citation: Oncol Rep. 2007 Dec;18(6):1469-73
references.pmid: 17982632
references.citation: Am J Transplant. 2009 Mar;9(3):592-600
references.pmid: 19191771
references.citation: Am J Gastroenterol. 2005 Dec;100(12):2708-16
references.pmid: 16393224
references.citation: Nucl Med Commun. 2013 Aug;34(8):749-57
references.pmid: 23689586
references.citation: J Hepatol. 2003 Feb;38(2):200-7
references.pmid: 12547409
references.citation: J Nucl Med. 2013 Oct;54(10):1710-6
references.pmid: 23970365
references.citation: J Hepatol. 2000 May;32(5):792-7
references.pmid: 10845666
references.citation: N Engl J Med. 1996 Mar 14;334(11):693-9
references.pmid: 8594428
references.citation: Hepatology. 1999 Jan;29(1):62-7
references.pmid: 9862851
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1485-91
references.pmid: 19224838
references.citation: Cancer J. 2004 Mar-Apr;10(2):121-7
references.pmid: 15130271
references.citation: Lancet Oncol. 2009 Jan;10(1):35-43
references.pmid: 19058754
references.citation: Oncology. 2007;72 Suppl 1:117-23
references.pmid: 18087192
references.citation: J Natl Compr Canc Netw. 2009 Apr;7(4):350-91
references.pmid: 19406039
references.citation: Hepatology. 2005 Nov;42(5):1208-36
references.pmid: 16250051
references.citation: Liver Int. 2006 Sep;26(7):781-8
references.pmid: 16911459
references.citation: Ann Surg. 2002 May;235(5):722-30; discussion 730-1
references.pmid: 11981219
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):427-33
references.pmid: 17255262